Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 128 Results From VALOR-HCM
Source: View publication →
The VALOR-HCM trial demonstrates that long-term mavacamten therapy in severely symptomatic patients with obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy (SRT) results in sustained reductions in the need for invasive SRT, alongside persistent improvements in NYHA class and left ventricular outflow tract gradients.
Key Findings
Study Design
Study Limitations
Clinical Significance
VALOR-HCM provides high-quality evidence that mavacamten is an effective, non-invasive pharmacological alternative for highly symptomatic patients with obstructive hypertrophic cardiomyopathy who have been referred for invasive septal reduction therapy, potentially allowing them to avoid or delay surgery or alcohol septal ablation.
Historical Context
Historically, management for patients with symptomatic obstructive HCM refractory to standard medical therapies (such as beta-blockers and calcium channel blockers) was largely limited to invasive septal reduction therapies (myectomy or alcohol ablation). Mavacamten, a first-in-class cardiac myosin inhibitor, represents a paradigm shift in HCM treatment by directly targeting the underlying molecular pathophysiology of hypercontractility.
Guided Discussion
High-yield insights from every perspective
What is the primary molecular mechanism of mavacamten, and how does it specifically target the pathophysiology of obstructive hypertrophic cardiomyopathy (oHCM)?
Key Response
Mavacamten is a first-in-class selective cardiac myosin inhibitor. It works by binding to cardiac myosin and shifting it into a 'super-relaxed' state, which reduces the number of myosin-actin cross-bridges that can form. In oHCM, there is an excess of these cross-bridges leading to hypercontractility and impaired relaxation; mavacamten normalizes this, thereby reducing the left ventricular outflow tract (LVOT) gradient and improving diastolic filling.
In a patient with oHCM who remains symptomatic despite maximally tolerated beta-blocker therapy, how do the results of the VALOR-HCM 128-week study change the management algorithm regarding septal reduction therapy (SRT)?
Key Response
The 128-week data from VALOR-HCM demonstrates that mavacamten can serve as a highly effective medical alternative to invasive SRT (myectomy or alcohol septal ablation). The study showed that the majority of patients who were previously eligible for SRT no longer met the clinical or hemodynamic criteria for the procedure after long-term mavacamten use, effectively allowing patients to avoid or significantly delay surgery while maintaining symptomatic improvement (NYHA class reduction).
The VALOR-HCM long-term extension reported that a small percentage of patients experienced a transient drop in left ventricular ejection fraction (LVEF) to <50%. How should this affect the clinical monitoring strategy for a patient on long-term cardiac myosin inhibitor therapy?
Key Response
Fellows must recognize the necessity of the REMS (Risk Evaluation and Mitigation Strategy) program. The 128-week data confirms that while LVEF reductions are generally reversible upon dose interruption or adjustment, they occur even in long-term stable patients. This necessitates continued, periodic echocardiographic monitoring of LVEF and LVOT gradients to ensure safety, as the drug’s potent effect on contractility carries a risk of inducing iatrogenic systolic heart failure.
Considering the 128-week results of VALOR-HCM, how would you counsel a 45-year-old symptomatic oHCM patient choosing between surgical myectomy and long-term mavacamten therapy?
Key Response
The counseling must pivot to a 'shared decision-making' model comparing the 'one-and-done' nature of surgical myectomy (which has decades of proven durability and may eliminate the need for daily specialized medications) versus the chronic medical management with mavacamten. While VALOR-HCM shows sustained benefit over 2.5 years, we still lack 10-20 year data on mavacamten, making the choice a balance between avoiding the immediate risks of open-heart surgery and the unknown long-term implications of chronic myosin inhibition.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critique the use of 'eligibility for septal reduction therapy' as a primary endpoint in the VALOR-HCM trial; what are the methodological strengths and weaknesses of using a guideline-based procedural recommendation as a proxy for clinical status?
Key Response
The strength lies in its clinical relevance, as it directly addresses a major milestone in the patient's disease trajectory (avoidance of surgery). However, the weakness is the inherent subjectivity of the 'referral' process and the potential for 'unblinding' in an open-label extension. If both the investigator and patient are aware of the treatment and the patient feels better, there is a strong bias against proceeding with surgery even if hemodynamic criteria are marginally met, which can inflate the perceived success of the drug in avoiding SRT.
As a reviewer, what concerns would you raise regarding the 'survivor bias' or attrition in the 128-week results of the VALOR-HCM study, and how might this affect the generalizability of the findings?
Key Response
A critical reviewer would note that patients who do not tolerate mavacamten or do not see early benefit are more likely to drop out of the long-term extension to pursue SRT or other treatments. Therefore, the 128-week results likely represent a 'best-case scenario' involving patients who are both responders and tolerant of the medication. The reported 90%+ avoidance of SRT may not apply to the entire initial intention-to-treat population if the attrition rate and reasons for discontinuation are not rigorously accounted for.
Based on the VALOR-HCM 128-week data, should mavacamten be recommended as a first-line therapy for symptomatic oHCM, and how does this evidence compare to the current Class 2a recommendation in the 2024 AHA/ACC guidelines?
Key Response
Currently, the 2024 AHA/ACC HCM guidelines recommend cardiac myosin inhibitors (Class 2a) for patients with persistent symptoms despite first-line agents (beta-blockers/calcium channel blockers). The VALOR-HCM data provides the level of evidence regarding 'durability' that might move the needle toward a Class 1 recommendation. However, the committee must consider that SRT still holds a Class 1 recommendation for refractory symptoms due to its historical success; mavacamten is currently positioned as an alternative to SRT, but not yet as a replacement for traditional first-line medical therapy (beta-blockers).
Clinical Landscape
Noteworthy Related Trials
PIONEER-HCM Trial
Tested
Mavacamten
Population
Symptomatic obstructive hypertrophic cardiomyopathy
Comparator
Placebo
Endpoint
Change in resting and post-exercise LVOT gradient
EXPLORER-HCM Trial
Tested
Mavacamten
Population
Symptomatic obstructive hypertrophic cardiomyopathy
Comparator
Placebo
Endpoint
Composite of change in pVO2 and NYHA functional class
VALOR-HCM Primary Analysis
Tested
Mavacamten
Population
Obstructive HCM patients eligible for septal reduction therapy
Comparator
Placebo
Endpoint
Decision to proceed with septal reduction therapy or continued eligibility at week 16
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis